echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Jixing Pharmaceutical Co., Ltd. over 100 million US dollars introduces tachycardia nasal administration therapy

    Jixing Pharmaceutical Co., Ltd. over 100 million US dollars introduces tachycardia nasal administration therapy

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 17, Milestone Pharmaceuticals, an innovative cardiovascular drug research and development company, announced that it has reached an exclusive license and cooperation agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil for paroxysmal rooms in Greater China.
    Patients with superior tachycardia (paroxysmal supraventricular tachycardia, PSVT) and other cardiovascular diseases
    .

    Etripamil is Milestone’s main research product and is a new type of calcium channel blocker designed to provide a rapid response treatment for occasional cardiovascular diseases
    .

    According to the terms of the agreement, Milestone will grant Ji Xing the exclusive license to develop and commercialize etripamil for PSVT patients in Greater China
    .


    Milestone will receive a US$15 million down payment from Jixing and a US$5 million equity investment from RTW


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.